natgillin/translations-raw huggingface dataset:
The iron component reacts with dietary phosphate in the gastrointestinal (GI) tract and precipitates phosphate as ferric phosphate.
Željezo reagira s fosfatom iz prehrane u gastrointestinalnom traktu i taloži fosfat u obliku željezovog fosfata.
These adverse reactions are characteristic of iron-containing medicinal products and abated with time with continued dosing.
Te nuspojave karakteristične su za lijekove koji sadrže željezo i s vremenom se smanjuju s nastavkom doziranja.
The ability of Fexeric to control serum phosphorus in CKD patients was principally evaluated in one long-term, pivotal Phase III trial (Study 304) in CKD 5D patients, and in one pivotal Phase II, 12 week, placebo-controlled trial (Study 204) in CKD ND patients with anaemia.
Sposobnost Fexerica da kontrolira razinu fosfora u serumu bolesnika s KBB-om prvotno je ocijenjena u jednom dugotrajnom pivotalnom ispitivanju faze III (Ispitivanje 304) u bolesnika s KBB 5D i u jednom pivotalnom, placebom kontroliranom ispitivanju faze II u trajanju od 12 tjedana (Ispitivanje 204) u bolesnika s KBB ND i anemijom.
The following medicines can affect or be affected by Fexeric: Fexeric contains iron and your doctor may need to adjust the dose of your other iron-containing
Fexeric sadrži željezo te će Vaš liječnik možda trebati prilagoditi dozu Vaših drugih lijekova koji
Common side effects (may affect up to 1 in 10 people): abdominal distension or bloating nausea, vomiting
Česte nuspojave (mogu se javiti kod do 1 na 10 osoba): bol/nelagoda u trbuhu nadimanje ili nadutost u trbuhu mučnina, povraćanje
Reductions in ESA use with Fexeric have been observed.
Opaženo je smanjenje primjene LSE s Fexericom.
During the 12-week treatment period, patients treated with Fexeric had a significant decrease in serum phosphorus, compared to the placebo group (p < 0.001 for treatment difference) (Table 3).
Tijekom 12-tjednog razdoblja liječenja, bolesnici koji su liječeni Fexericom imali su značajno smanjenje razine fosfora u serumu u usporedbi sa skupinom koja je uzimala placebo (p< 0,001 za razliku u liječenju) (Tablica 3).
Adverse reactions reported in CKD 5D and CKD ND patients are presented in Tables 1 and 2, respectively.
Nuspojave prijavljene u bolesnika s KBB 5D i KBB ND prikazane su u Tablici 1.,
Name and address of the manufacturer(s) responsible for batch release
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet
The Fexeric-bound phosphorus is then excreted from your body in faeces.
Fosfor vezan na Fexeric tada se izlučuje iz Vašeg tijela stolicom.
Table 2: Adverse reactions observed during clinical studies in which Fexeric was administered in CKD ND patients.
Tablica 2.: Nuspojave opažene tijekom kliničkih ispitivanja u kojima je Fexeric primijenjen u
System Organ Class by MedDRA
Klasifikacija organskih sustava prema
Temporarily discontinue Fexeric if the serum phosphorus is < 3 mg/dl and resume at a lower dose once the serum phosphorus has returned to the target range.
Ako je razina fosfora u serumu < 3 mg/dl potrebno je privremeno prekinuti primjenu Fexerica i nastaviti s primjenom manje doze nakon što se vrijednost fosfora u serumu vrati unutar ciljnog
The recommended starting dose of Fexeric is 3 to 6 g (3 to 6 tablets) per day based on serum
Preporučena početna doza Fexerica je 3 do 6 g dnevno (3 do 6 tableta), ovisno o razini fosfora u
In the pivotal non-dialysis study 204 CKD ND patients treated with Fexeric had a significant increase in serum TSAT, ferritin and haemoglobin levels compared to the placebo group after 12 weeks of treatment (p< 0.001 for treatment difference for each parameter) (Table 4).
U pivotalnom ispitivanju 204 na bolesnicima koji nisu na dijalizi, bolesnici s KBB ND liječeni Fexericom imali su značajno povećanje razina TSAT-a, feritina i hemoglobina u serumu u usporedbi sa skupinom liječenom placebom nakon 12 tjedana liječenja (p< 0,001 za razliku u liječenju za svaki parametar) (Tablica 4).
Urinary phosphorus excretion and FGF-23 were also significantly decreased relative to baseline in the CKD ND patients treated with Fexeric compared to patients treated with placebo.
Izlučivanje fosfora urinom i FGF-23 (engl. fibroblast growth factor 23) također su znatno smanjeni u odnosu na početnu vrijednost u bolesnika s KBB ND koji su liječeni
§ Primary endpoint in Study 304; Co-primary endpoint in Study 204.
§ Koprimarni ishod u Ispitivanju 204.
Serum phosphorus concentrations should be monitored within 2 to 4 weeks of starting or changing the dose of Fexeric, and approximately every 2-3 months when stable.
Titracija doze Koncentracije fosfora u serumu trebaju se nadzirati unutar 2 do 4 tjedna od početka ili promjene doze
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih dodatnih pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili
Table 4: Summary of results on iron homeostasis at Week 12 and Week 52 in Study 304 (CKD 5D) and at Week 12 in Study 204 (CKD ND)
Tablica 4: Sažetak rezultata homeostaze željeza u 12. i 52. tjednu Ispitivanja 304 (KBB 5D) te u 12. tjednu Ispitivanja 204 (KBB ND)
Fexeric contains sunset yellow FCF (E110) and Allura Red AC (E129)
Fexeric sadrži boje Sunset Yellow FCF (E110) i Allura Red AC (E129)
Patients not on dialysis require the lower starting dose: 3 tablets daily, in separated doses, with or
Bolesnicima koji nisu na dijalizi potrebna je niža početna doza: 3 tablete dnevno u podijeljenim dozama uz glavne dnevne obroke ili odmah nakon njih.
Table 3: Summary of efficacy parameters on phosphorus homeostasis at Week 12 and Week 52 in Study 304 (CKD 5D) and at Week 12 in Study 204 (CKD ND)
Tablica 3: Sažetak parametara djelotvornosti za homeostazu fosfora u 12. i 52. tjednu Ispitivanja 304 (KBB 5D) te u 12. tjednu Ispitivanja 204 (KBB ND)
Diarrhoea, discoloured faeces Abdominal pain/discomfort/distension, constipation, nausea, vomiting Abnormal faeces, bowel movement irregularity, dry mouth, dysgeusia, dyspepsia, flatulence, frequent bowel movements, gastritis, gastritis erosive, gastrooesophageal reflux disease, haematemesis, peptic ulcer
mučnina, povraćanje neuobičajeni feces, neredovito pražnjenje crijeva, suha usta, disgeuzija, dispepsija, flatulencija, česta pražnjenja crijeva, gastritis, erozivni gastritis, gastroezofagealna refluksna bolest, hematemeza, peptički ulkus
After first opening of the bottle, use within 60 days.
Upotrijebiti unutar 60 dana od prvog otvaranja boce.
The most common side effects (affecting more than 1 in 10 people) in patients not on dialysis also
Najčešće nuspojave (javljaju se kod više od 1 na 10 osoba) u bolesnika koji nisu na dijalizi također su povezane sa želucem ili crijevima:
The recommended dose is: - starting dose for adults: 3 to 6 tablets daily, in separated doses, with or immediately after main meals of the day.
- početna doza za odrasle: 3 do 6 tableta dnevno u podijeljenim dozama uz glavne dnevne obroke ili odmah nakon njih.
In the remaining non-dialysis studies, a total of 3 serious adverse reactions reported in 2 patients were gastrointestinal in nature (gastrointestinal ulcer, gastric polyps and colonic polyps).
U preostalim ispitivanjima bolesnika koji se ne liječe dijalizom prijavljene su ukupno 3 ozbiljne nuspojave u 2 bolesnika i one su bile gastrointestinalnog karaktera
Following absorption, citrate is converted
Nakon apsorpcije, tkiva pretvaraju citrat u bikarbonat.
Peach-coloured, oval shaped, film-coated tablet, embossed with “KX52”.
Ovalna filmom obložena tableta boje breskve s utisnutom oznakom „KX52”.
If you are able to become pregnant, you must use birth control during treatment.
Ako ste žena reproduktivne dobi, za vrijeme liječenja morate upotrebljavati zaštitu od začeća.
Skin and subcutaneous tissue disorders
Poremećaji kože i potkožnog tkiva Manje često:
- maximum dose: 12 tablets daily, in separated doses, with or immediately after meals of the
- maksimalna doza: 12 tableta dnevno u podijeljenim dozama uz glavne dnevne obroke ili
*Proportion of patients achieving serum phosphorus ≤ 5.5 mg/dl in CKD 5D patients; **Proportion of patients achieving serum phosphorus ≤ 4.0 mg/dl in CKD ND patients NAP: not applicable; SD: standard deviation
§ Primarni ishod Ispitivanja 304; koprimarni ishod Ispitivanja 204. * Udio bolesnika s KBB 5D koji su postigli razinu fosfora u serumu ≤ 5,5 mg/dl ** Udio bolesnika s KBB ND koji su postigli razinu fosfora u serumu ≤ 4,0 mg/dl NP: nije primjenjivo; SD: standardna devijacija
The dose of phosphate binder was titrated as needed to maintain serum phosphorus levels between 3.5 and 5.5 mg/dl, to a maximum of 12 g/day.
Doza vezača fosfata bila je titrirana po potrebi, do najviše 12 g dnevno, kako bi se održale razine fosfora u serumu između 3,5 i 5,5 mg/dl.
for sevelamer only)
Početna razina fosfora u serumu samo za sevelamer)
Decreased appetite, hyperkalaemia, hypophosphataemia, increased appetite Dizziness, headache Palpitations, dyspnoea Malignant hypertension
povećani apetit omaglica, glavobolja palpitacije, dispneja maligna hipertenzija
Talk to your doctor or pharmacist before taking Fexeric if you have: too much iron in your body bowel inflammation
Obratite se svom liječniku ili ljekarniku prije nego što uzmete Fexeric ako imate:
There are no data regarding the use of ferric citrate coordination complex in pregnant women.
Ne postoje podaci o primjeni komplesknog spoja željezovog citrata u trudnica.
NAP
Nuspojava
Increases in ferritin and TSAT above safety thresholds are observed with Fexeric use.
Prilikom primjene Fexerica opažena su povišenja feritina i TSAT-a iznad sigurnosnih graničnih vrijednosti.
HDPE bottles with child-resistant closure with desiccant.
HDPE boce sa sigurnosnim zatvaračem za djecu i sredstvom za sušenje.
All serious adverse reactions were gastrointestinal in nature (abdominal pain, constipation, diarrhoea, gastritis, gastritis erosive, and haematemesis).
Sve su ozbiljne nuspojave bile gastrointestinalnog karaktera (bol u abdomenu, konstipacija,
CKD patients who are not on dialysis require the lower starting dose, 3 g (3 tablets) per day.
Bolesnicima s KBB-om koji se ne liječe dijalizom potrebna je niža početna doza od 3 g dnevno (3
Package leaflet: Information for the patient Fexeric 1 g film-coated tablets ferric citrate coordination complex This medicine is subject to additional monitoring.
Uputa o lijeku: Informacije za bolesnika Fexeric 1 g filmom obložene tablete kompleksni spoj željezovog citrata
Data on primary and secondary pharmacodynamics, safety pharmacology and pharmacokinetics of Fexeric were derived from the repeat dose toxicology studies, and did not reveal safety concerns for humans.
Podaci o primarnoj i sekundarnoj farmakodinamici, sigurnosnoj farmakologiji i farmakokinetici
Pregnancy and women of childbearing potential
4.6 Plodnost, trudnoća i dojenje Trudnoća i žene u reproduktivnoj dobi
Bronchitis
Nuspojava bronhitis
Each film-coated tablet contains 1 g of ferric citrate coordination complex (equivalent to 210 mg of
Jedna filmom obložena tableta sadrži 1g kompleksnog spoja željezovog citrata (što odgovara 210 mg
During the subsequent 4-week placebo-controlled period, the serum phosphorus levels remained stable in patients receiving Fexeric (mean decrease of 0.24 mg/dl), whereas patients receiving placebo had a mean increase of 1.79 mg/dl (p < 0.0001 for treatment difference).
Tijekom narednog 4-tjednog placebom kontroliranog razdoblja razine fosfora u serumu ostale su stabilne u bolesnika koji su primali Fexeric (srednja vrijednost smanjenja od 0,24 mg/dl), dok su bolesnici koji su primali placebo imali srednju vrijednost povećanja od
and immunosuppressant (methotrexate) medications showed the potential to interact with Fexeric: any of these or other medicinal products that have the potential to interact with Fexeric, should be taken at least 2 hours before or after Fexeric.
U in vitro ispitivanjima neki su antibiotici (doksiciklin, cefdinir), antikonvulzivi (natrijev valproat), antidepresivi (sertralinklorid), bisfosfonati (natrijev alendronat), antiparkinsonici (levodopa) i imunosupresivi (metotreksat) pokazali potencijal za interakcije s Fexericom: bilo koji od tih lijekova ili drugi lijekovi s potencijalom za interakcije s Fexericom moraju se uzimati najmanje 2 sata prije ili
Monitoring blood levels of these medicines may also be considered: - ciprofloxacin, doxycycline, cefdinir: medicines to treat bacterial infections - valproic acid: a medicine to treat epilepsy and mental disorders - sertraline: a medicine to treat depression - methotrexate: a medicine to treat rheumatoid arthritis, cancer and the skin disease, psoriasis - alendronate: a medicine to treat decreased bone mass and density - levodopa: a medicine to treat Parkinson's disease - levothyroxine: a medicine to treat thyroid hormone deficiency
- alendronat: lijek za liječenje smanjenja koštane mase i gustoće - levodopa: lijek za liječenje Parkinsonove bolesti - levotiroksin: lijek za liječenje manjka hormona štitnjače
In CKD 5D patients, the primary evaluation of safety is based on the integrated analysis of data from 4 studies involving 557 CKD 5D patients treated with Fexeric for up to 1 year.
U bolesnika s KBB 5D primarna procjena sigurnosti temelji se na integriranoj analizi podataka iz 4
Pulmonary oedema, wheezing
pruritus, osip
The active substance is ferric citrate coordination complex.
Djelatna tvar Fexerica je kompleksni spoj željezovog citrata.
Active severe gastrointestinal disorders (e.g. gastrointestinal bleeding) Haemochromatosis or laboratory tests indicating possible haemochromatosis Other iron overload (primary or secondary) syndromes
Hemokromatoza ili nalazi laboratorijskih pretraga koji ukazuju na moguću hemokromatozu
Each film-coated tablet contains 1 g of ferric citrate coordination complex (equivalent to 210 mg of ferric iron).
Jedna filmom obložena tableta sadrži 1 g kompleksnog spoja željezovog citrata (što odgovara 210 mg trovalentnog željeza)
Fexeric should be temporarily discontinued if serum ferritin exceeds 800 ng/ml.
Ako feritin u serumu prelazi 800 ng/ml, primjenu Fexerica treba privremeno prekinuti.
No dosage reduction is considered necessary but patients with hepatic impairment should initiate treatment with the lower starting dose, 3 g (3 tablets) per day (see section 5.1).
Smatra se da nije nužno smanjenje doze, no bolesnici s oštećenjem jetre trebaju započeti liječenje s nižom početnom dozom od
See the end of section 4
Za postupak prijavljivanja nuspojava, pogledajte dio 4.
abdominal pain/discomfort, nausea, vomiting, haemorrhoids, haematochezia, mucous stools, dyspepsia, flatulence, dry mouth
Poremećaji metabolizma i prehrane hipofosfatemija proljev, konstipacija, promjena boje fecesa bol /nelagoda u abdomenu, mučnina, povraćanje, hemoroidi, hematohezija, sluzave stolice, dispepsija, flatulencija, suha usta
Adverse Reaction
inkontinencija
In the pivotal non-dialysis study 204, a total of 148 CKD ND patients with hyperphosphatemia and iron deficiency anaemia received treatment with study drug; there were 141 patients in the intent-totreat population (Fexeric: 72 patients; Placebo: 69 patients).
populacija koju se namjeravalo liječiti (ITT, engl. intent-to-treat) obuhvaćala je 141 bolesnika (Fexeric: 72 bolesnika; placebo: 69 bolesnika).
The following side effects have been reported with Fexeric in dialysis patients: Very common side effects (may affect more than 1 in 10 people):
Vrlo česte nuspojave (mogu se javiti kod više od 1 na 10 osoba):
As a secondary endpoint in dialysis patients, and a co-primary endpoint in non-dialysis patients, the ability of Fexeric to increase iron stores was also evaluated.
Također je ocijenjena sposobnost Fexerica da poveća zalihe željeza kao sekundarni ishod u bolesnika liječenih dijalizom i kao koprimarni ishod u bolesnika koji nisu liječeni dijalizom.
- if you are allergic to ferric citrate coordination complex or any of the other ingredients of this medicine (listed in section 6) - if you have low levels of phosphorus in your blood - if you have a severe stomach or bowel disease such as stomach or bowel bleeding
- ako imate tešku želučanu ili crijevnu bolest kao što je želučano ili crijevno krvarenje;
Hypophosphataemia
Klinička djelotvornost
This medicine contains ferric citrate coordination complex as the active substance.
Djelatna tvar u ovom lijeku jest kompleksni spoj željezovog citrata.
Also contains sunset yellow FCF (E110), Allura Red AC (E129), see the package leaflet for futher
Također sadrži boje Sunset Yellow FCF (E110) i Allura Red AC (E129).
Uncommon:
SN: NN:
They are supplied in one pack size of
Dostavljaju se u pakiranju jedne veličine koje sadrži 200 tableta po boci.
Do not store above 25°C Keep the bottle tightly closed in order to protect from moisture.
Ne čuvati na temperaturi iznad 25°C.
The most commonly reported adverse reactions in dialysis-dependent chronic kidney disease (CKD 5D) patients during treatment were discoloured faeces and diarrhoea occurring in 18% and 13% of patients, respectively.
(KBB 5D) bile su promjena boje fecesa koja se javila u 18 %, i proljev koji se javio u 13 % bolesnika.
Clinical consequences are unknown.
Kliničke posljedice nisu poznate.
Target organ
Ciljni organ
Other body areas
Druga područja tijela
<Product name> is approved for use in children above two years of age.
<Naziv lijeka> je odobren za primjenu u djece starije od dvije godine.
This includes retention in the brain and in other tissues and organs.
To uključuje zadržavanje u mozgu i drugim tkivima i organima.
Brain and spine
Mozak i kralješnica
Because of the lack of information on repeated administration, <Product name> injections should not be repeated unless the interval between injections is at least 7 days.
Zbog nedostatka informacija o ponovljenoj primjeni, injekcije <Naziv lijeka>se ne smiju ponavljati osim ako je interval između injekcija najmanje 7 dana.
• part for healthcare professionals: Post-contrast imaging acquisition:
• dio za zdravstvene radnike: Dobivanje prikaza nakon kontrasta:
o Accumulation in the body <Product name> works because it contains a metal called gadolinium.
o Nakupljanje u tijelu <Naziv lijeka> djeluje zato što sadrži metal koji se naziva gadolinij.
• Section 2: What you need to know before you are given <product name>
• Dio 2: Što morate znati prije nego primite <naziv lijeka>
Intravenous gadobenic acid (restriction of the indication - all references to other indications should be removed across the Product Information)
Gadobenatna kiselina za intravensku primjenu (ograničenje indikacije - iz informacija o lijeku moraju se ukloniti sve reference na druge indikacije)
• Section 1 What <Product name> is and what it is used for
• Dio 1 Što je <Naziv lijeka> i za što se koristi
The amount in millilitre you will be injected depends on how much you weigh in kilogram of body weight.
Količina koja će Vam biti ubrizgana u mililitrima ovisi o Vašoj tjelesnoj težini u kilogramima.
Dynamic imaging:
Dinamičko oslikavanje:
Patients undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group.
Bolesnici koji se podvrgavaju transplantaciji jetre su pod pojačanim rizikom jer je incidencija akutnog zatajenja bubrega visoka u ovoj skupini.
• Assessment of myocardial perfusion
•procjena perfuzije miokarda
Studies have shown that small amounts of gadolinium can remain in the body, including the brain.
Ispitivanja su pokazala da male količine gadolinija mogu ostati u tijelu, uključujući i mozak.
• Specific applications in the heart include measurement of myocardial perfusion under pharmacological stress conditions and viability diagnostics ("delayed enhancement").
• Specifične primjene u srcu uključuju mjerenje perfuzije miokarda pod farmakološkim stresnim uvjetima i dijagnostici funkcije („odgođeno poboljšanje“).
Immediately following bolus injection.
Neposredno nakon bolus injekcije.
There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with acute or chronic severe renal impairment (GFR< 30ml/min /1.73 m2).
Prijavljeni su slučajevi nefrogene sistemske fibroze (NSF) povezane s primjenom nekih kontrastnih sredstava koja sadrže gadolinij u bolesnika s akutnim ili kroničnim teškim oštećenjem bubrega (GFR <30 ml/min/1,73 m2).
This has not been seen following the small amounts given with injections into the joint.
To nije bilo opaženo nakon primjene malih količina koje se daju injekcijom u zglob.
The existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below.
Izmjene i dopune odgovarajućih dijelova informacija o lijeku Postojeće informacije o lijeku treba prilagoditi (umetnuti, zamijeniti ili izbrisati tekst, kako je prikladno) kako bi odgovarale dogovorenom tekstu koji je naveden niže.
Signal intensity increases and non-clinical data show that gadolinium is released from linear GdCAs.
Pojačanje intenziteta signala i neklinički podaci pokazuju da se gadolinij oslobađa iz linearnih gadolinijskih kontrastnih sredstava.
The dose should be calculated based on the patient's body weight, and should not exceed the recommended dose per kilogram of body weight detailed in this section.
Dozu treba izračunati na temelju tjelesne težine bolesnika, te ona ne smije biti viša od preporučene doze po kilogramu tjelesne težine navedene u ovom dijelu.
Brain and Spine up to 60 minutes after the administration.
Mozak i kralješnica Do 60 minuta nakon primjene.
It helps your doctor to identify any abnormalities of your liver brain/spine, arteries or other parts of your body.
Pomaže liječniku u otkrivanju bilo kakvih promjena na jetri mozgu/kralješnici, arterijama ili drugim dijelovima Vašeg tijela.
These amendments to the relevant sections of the product information are the outcome of the referral procedure.
Ove izmjene i dopune odgovarajućih dijelova informacija o lijeku rezultat su arbitražnog postupka.
The lowest dose that provides sufficient enhancement for diagnostic purposes should be used.
Potrebno je primijeniti najnižu dozu koja osigurava dovoljno pojačanje prikaza za dijagnostičke svrhe.
• Section 3 How to use <Product name>
• Dio 3: Kako primjenjivati <Naziv lijeka>
between 40 and 120 minutes following the injection, depending on the individual imaging needs.
između 40 i 120 minuta nakon injekcije, ovisno o potrebama snimanja u pojedinom slučaju.
<Product name> is injected into a vein, usually in your arm just before the MRI scan.
<Naziv lijeka> se ubrizgava u venu, obično ruke, neposredno prije pregleda MR-om.
Retention of gadolinium in the brain has not been identified for intra-articular administration.
Zadržavanje gadolinija u mozgu nije zabilježeno kod intraartikularne primjene.
Liver, kidneys, urinary tract , adrenal glands
Jetra, bubrezi, urinarni trakt, adrenalne žlijezde
• MRI of the brain and spine in adults and children above the age of 2 years, where it improves the detection of lesions and provides diagnostic information additional to that obtained with unenhanced MRI (see section 5.1).
• MR mozga i kralježnice u odraslih i djece u dobi iznad 2 godine, gdje pojačava detekciju lezija i osigurava dodatne dijagnostičke informacije uz one dobivene s MR-om bez pojačanja signala (vidjeti dio 5.1).
A T1-weighted, gradient-echo sequence with a time resolution of 2 minutes or less should be acquired before contrast injection and repeated several times over a period of 5 to 8 min after a rapid intravenous contrast bolus injection.
T1-mjerena, dinamička akvizicija s vremenskom razlučivosti od 2 minute ili manje prije injekcije kontrasta te ponovljena nekoliko puta tijekom perioda od 5-8 minuta nakon brze intravenske bolus injekcije kontrasta.
Delayed imaging: between 40 and 120 minutes following the injection, depending on the individual imaging needs.
Odgođeno oslikavanje: između 40 i 120 minuta nakon injekcije, ovisno o potrebama snimanja u pojedinom slučaju.